MedPath

Ovidrel

OVIDREL PreFilled Syringe(choriogonadotropin alfa injection)

Approved
Approval ID

a683e58a-63ea-44b8-a326-1a99a537bcf2

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 26, 2023

Manufacturers
FDA

EMD Serono, Inc.

DUNS: 088514898

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

choriogonadotropin alfa

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code44087-1150
Application NumberBLA021149
Product Classification
M
Marketing Category
C73585
G
Generic Name
choriogonadotropin alfa
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateDecember 26, 2023
FDA Product Classification

INGREDIENTS (7)

CHORIOGONADOTROPIN ALFAActive
Quantity: 250 ug in 0.5 mL
Code: 6413W06WR3
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
POLOXAMER 188Inactive
Code: LQA7B6G8JG
Classification: IACT
METHIONINEInactive
Code: AE28F7PNPL
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
PHOSPHORIC ACIDInactive
Code: E4GA8884NN
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.